Orbits Oncology

Orbits Oncology is a private, pre-revenue biotech platform company founded in 2019 and incorporated in the USA in 2023. The company has developed a device-agnostic, AI-powered digital platform that analyzes images of patient-derived tumor organoids to provide actionable insights for drug discovery and clinical research. Its core value proposition is automating the analysis of living tumor models to identify treatment-resistant subclones and predict patient outcomes, thereby aiming to improve clinical trial stratification and personalized treatment strategies. The company is currently building a waitlist for its platform and has published collaborative research in npj Precision Oncology.

AI-powered computational platform for automated analysis of patient-derived tumor organoids. It uses high-resolution computer vision and machine learning to detect, track, and extract multiparametric features from organoid imagery to generate drug discovery insights and predictive patient models.

Competition includes providers of organoid services (e.g., Crown Bioscience), vendors of high-content imaging systems with analysis software (e.g., PerkinElmer), and AI-driven digital pathology companies (e.g., PathAI). Orbits differentiates through its specific focus on 3D organoid analysis, device-agnostic SaaS model, and published research linking its outputs to clinical phenotypes.